Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis
暂无分享,去创建一个
H. Yang | Y. Wang | H. Pan | N. Li | J. Hou | H. Zhu | L. Wang | W. Liang | L. Gao | Y. Jiang | B. Wang | L. You | S. Chen | Y. Wang
[1] L. Wilkins. Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects , 2015, Journal of the American Heart Association.
[2] P. Raskin,et al. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study , 2015, Journal of diabetes research.
[3] A. Cincotta,et al. Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats , 2014, Diabetology & Metabolic Syndrome.
[4] N. Sengupta,et al. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial , 2014, Indian journal of pharmacology.
[5] W. Drake,et al. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. , 2014, The Journal of clinical endocrinology and metabolism.
[6] A. Cincotta,et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[7] D. Bell. Focusing on Cardiovascular Disease in Type 2 Diabetes Mellitus: An Introduction to Bromocriptine QR , 2012, Postgraduate medicine.
[8] P. García-Pavía,et al. No clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma , 2012, Clinical endocrinology.
[9] S. Zacharieva,et al. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. , 2012, European journal of endocrinology.
[10] Z. Bloomgarden,et al. Hypoglycemia in Type 2 Diabetes: Current Controversies and Changing Practices , 2012, Front. Endocrin..
[11] H. Anthony. Weighted Effects of Bromocriptine Treatment on Glucose Homeostasisduring Hyperglycemic versus Euglycemic Clamp Conditions in Insulin Resistant Hamsters: Bromocriptine as a Unique Postprandial Insulin Sensitizer , 2012 .
[12] C. Boguszewski,et al. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas , 2012, Pituitary.
[13] A. Cincotta,et al. Randomized Clinical Trial Assessing the Efficacy and Safety of Bromocriptine-QR when Added to Ongoing Thiazolidinedione Therapy in Patients with Type 2 Diabetes Mellitus , 2011 .
[14] D. Bell. Why does quick‐release bromocriptine decrease cardiac events? , 2011, Diabetes, obesity & metabolism.
[15] M. Ezzati,et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.
[16] Jaiprakash Ramanand,et al. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes , 2011, Indian journal of endocrinology and metabolism.
[17] R. DeFronzo. Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes , 2011, Diabetes Care.
[18] S. Kalra,et al. Dopamine: the forgotten felon in type 2 diabetes. , 2011, Recent patents on endocrine, metabolic & immune drug discovery.
[19] M. Rubinstein,et al. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. , 2010, Endocrinology.
[20] Michael A. Via,et al. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes , 2010, Diabetes, metabolic syndrome and obesity : targets and therapy.
[21] C. O'connor,et al. Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes , 2010, Diabetes Care.
[22] A. Cincotta,et al. Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes , 2010, Expert opinion on pharmacotherapy.
[23] G. Reynolds,et al. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. , 2010, Pharmacology & therapeutics.
[24] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[25] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[26] Y. Chan,et al. Bromocriptine use and the risk of valvular heart disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[27] F. Andersohn,et al. Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists , 2009, Movement disorders : official journal of the Movement Disorder Society.
[28] A. Cincotta,et al. Quick release bromocriptine (Cycloset™) a novel treatment for type 2 diabetes also demonstrates improvements in blood pressure , 2009 .
[29] W. Poewe,et al. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.
[30] E. Chung,et al. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists , 2006, Movement disorders : official journal of the Movement Disorder Society.
[31] S. Carobbio,et al. Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion* , 2005, Journal of Biological Chemistry.
[32] Werner Poewe,et al. Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 , 2005, Movement disorders : official journal of the Movement Disorder Society.
[33] Charles M Peterson,et al. Tests of glycemia in diabetes. , 1995, Diabetes care.
[34] N. Yanagisawa,et al. Randomized, double‐blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[35] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[36] J. Lancaster,et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. , 2000, Diabetes care.
[37] A. Cincotta,et al. Chronic Ventromedial Hypothalamic Infusion of Norepinephrine and Serotonin Promotes Insulin Resistance and Glucose Intolerance , 1999, Neuroendocrinology.
[38] A. Cincotta,et al. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. , 1999, Expert opinion on investigational drugs.
[39] A. Cincotta,et al. Bromocriptine Reduces Obesity, Glucose Intolerance and Extracellular Monoamine Metabolite Levels in the Ventromedial Hypothalamus of Syrian Hamsters , 1998, Neuroendocrinology.
[40] D. Brooks,et al. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study , 1998, Movement disorders : official journal of the Movement Disorder Society.
[41] A. Cincotta,et al. Effects of a Quick-Release Form of Bromocriptine (Ergoset) on Fasting and Postprandial Plasma Glucose, Insulin, Lipid, and Lipoprotein Concentrations in Obese Nondiabetic Hyperinsulinemic Women , 1997, Diabetes Care.
[42] O. Rascol,et al. Prevalence of orthostatic hypotension in Parkinson’s disease , 1997, Journal of neurology, neurosurgery, and psychiatry.
[43] A. Cincotta,et al. Circadian rhythms regulate the- expression of the thrifty genotypelphenotype , 1996 .
[44] M. Lam,et al. Domperidone for Drug-Induced Orthostatic Hypotension-A Review , 1992 .
[45] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[46] A. Tadepalli,et al. Cardiovascular actions of bromocriptine: evidence for a neurogenic mechanism. , 1979, The Journal of pharmacology and experimental therapeutics.
[47] S. Kaye,et al. Letter: Bromocriptine and hypertension. , 1976, Lancet.